Product image of Granisetrón Altan (Granisetron) supplied by GNH India

Granisetrón Altan

Active Ingredient:
Granisetron
Origin:
EU

Granisetrón Altan (Granisetron)

Granisetrón Altan is a prescription medication that contains the active ingredient granisetron, a selective 5‑HT3 receptor antagonist, supplied for intravenous administration. It is marketed in the European Union and is used as an antiemetic to help prevent and treat nausea and vomiting associated with chemotherapy and postoperative settings. The product’s specific strength and formulation details are defined by the manufacturer according to regulatory guidelines and clinical practice.

Manufacturer / TM Owner

Altan Pharmaceuticals S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Granisetrón Altan is indicated for the prevention and treatment of nausea and vomiting in specific clinical situations.

  • Prevention of chemotherapy‑induced nausea and vomiting (CINV) in adult patients receiving moderately to highly emetogenic regimens.
  • Treatment of acute and delayed CINV when oral antiemetics are insufficient or not tolerated.
  • Prevention of postoperative nausea and vomiting (PONV) following surgical procedures requiring general anesthesia.
  • Adjunct therapy in patients undergoing radiotherapy where nausea is anticipated.

Side Effects

The safety profile of Granisetrón Altan includes a range of observed adverse events, most of which are mild to moderate in intensity.

Common

  • Headache
  • Constipation
  • Diarrhea
  • Fatigue
  • Dizziness

Serious

  • Severe allergic reaction (anaphylaxis)
  • Cardiac arrhythmia
  • Prolonged QT interval
  • Serotonin syndrome (when combined with serotonergic agents)

Precautions & Warnings

Before initiating Granisetrón Altan, clinicians should evaluate patient history and consider specific safety considerations.

  • Assess for known hypersensitivity to granisetron or other 5‑HT3 antagonists.
  • Use caution in patients with a history of cardiac conduction disorders or prolonged QT interval.
  • Evaluate renal and hepatic function, as dose adjustments may be required in severe impairment.
  • Monitor for signs of serotonin syndrome if the patient is receiving serotonergic medications.
  • Consider pregnancy and lactation status; safety data are limited.

Avoid Interactions

Granisetrón Altan may interact with other medicines, influencing its efficacy or safety profile.

Avoid

  • Concurrent use with other 5‑HT3 antagonists, which can increase the risk of cardiac effects.
  • Combination with potent CYP3A4 inhibitors (e.g., ketoconazole) that may raise granisetron plasma levels.

Use with caution

  • Serotonergic agents such as SSRIs, SNRIs, or triptans, due to potential serotonin syndrome.
  • Drugs that prolong QT interval (e.g., certain antiarrhythmics, antipsychotics).
  • Anesthetic agents that may affect cardiac rhythm when used together.

Frequently Asked Questions

Granisetrón Altan is a prescription drug that contains granisetron, a selective 5‑HT3 receptor antagonist. By blocking serotonin receptors in the central nervous system and gastrointestinal tract, it reduces the signals that trigger nausea and vomiting.

It is commonly prescribed to prevent and treat nausea and vomiting caused by chemotherapy (CINV) and to prevent postoperative nausea and vomiting (PONV) after surgery.

Granisetrón Altan is given by intravenous injection under the supervision of a healthcare professional, usually shortly before the emetogenic stimulus such as chemotherapy or surgery.

The most frequently reported adverse effects include headache, constipation, diarrhea, fatigue, and dizziness, which are generally mild and transient.

Yes. Serious reactions such as severe allergic response (anaphylaxis), cardiac arrhythmia, prolonged QT interval, or signs of serotonin syndrome should be evaluated promptly by a medical professional.

Clinicians should check for hypersensitivity to granisetron, assess cardiac history (especially QT prolongation), evaluate renal and hepatic function, and consider pregnancy or breastfeeding status.

Severe renal or hepatic impairment may require dose adjustment or closer monitoring, as these conditions can alter the drug’s clearance and increase the risk of side effects.

Concurrent use with other 5‑HT3 antagonists and strong CYP3A4 inhibitors should be avoided because they can increase granisetron levels and cardiac risk.

Safety data for use in pregnancy and lactation are limited; the drug should only be used if the potential benefit justifies the potential risk to the fetus or infant.

Granisetrón Altan is formulated for intravenous use, which provides rapid onset of action. Its safety and efficacy profile are comparable to other 5‑HT3 antagonists, but formulation and dosing may differ.

No. Granisetrón Altan is a prescription‑only medication and must be prescribed by a qualified healthcare professional.

Because Granisetrón Altan is administered intravenously in a controlled setting, missed doses should be reported to the treating clinician, who will determine the appropriate next step.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Granisetron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT